View in EDS HTML Full Text PDF Full Text

The FSTL1-DIP2A axis is a significant biomarker for predicting anti-PD1 therapeutic efficacy in advanced gastric cancer.

Saved in:
Bibliographic Details
Title: The FSTL1-DIP2A axis is a significant biomarker for predicting anti-PD1 therapeutic efficacy in advanced gastric cancer.
Authors: Kudo-Saito C; Department of Immune Medicine, National Cancer Center Research Institute, Tokyo, Japan. ckudo@ncc.go.jp., Imazeki H; Department of Immune Medicine, National Cancer Center Research Institute, Tokyo, Japan.; Department of Gastrointestinal Medical Oncology, National Cancer Center Hospital, Tokyo, Japan., Nagashima K; Biostatistics Unit, Clinical and Translational Research Center, Keio University Hospital, Tokyo, Japan., Shoji H; Department of Gastrointestinal Medical Oncology, National Cancer Center Hospital, Tokyo, Japan., Tsugaru K; Division of Gastroenterology and Hepatology, Keio University Hospital, Tokyo, Japan., Takahashi N; Department of Gastroenterology, Saitama Cancer Center, Saitama, Japan., Kawakami T; Division of Gastrointestinal Oncology, Shizuoka Cancer Center, Shizuoka, Japan., Amanuma Y; Clinical Trial Promotion Department, Chiba Cancer Center, Chiba, Japan., Wakatsuki T; Department of Gastrointestinal Medical Oncology, Cancer Institute Hospital of JFCR, Tokyo, Japan., Nagashima F; Department of Medical Oncology, Faculty of Medicine, Kyorin University, Tokyo, Japan., Narita Y; Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan., Yamamoto Y; Department of Gastroenterology, University of Tsukuba Hospital, Tsukuba, Japan., Kizawa R; Department of Medical Oncology, Toranomon Hospital, Tokyo, Japan., Muro K; Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan., Boku N; Department of Gastrointestinal Medical Oncology, National Cancer Center Hospital, Tokyo, Japan.; Department of Medical Oncology and General Medicine, IMS Hospital, Institute of Medical Science, University of Tokyo, Tokyo, Japan.
Source: Cancer immunology, immunotherapy : CII [Cancer Immunol Immunother] 2025 Nov 18; Vol. 74 (12), pp. 379. Date of Electronic Publication: 2025 Nov 18.
Publication Type: Journal Article
Journal Info: Publisher: Springer Verlag Country of Publication: Germany NLM ID: 8605732 Publication Model: Electronic Cited Medium: Internet ISSN: 1432-0851 (Electronic) Linking ISSN: 03407004 NLM ISO Abbreviation: Cancer Immunol Immunother Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 41251805
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: The FSTL1-DIP2A axis is a significant biomarker for predicting anti-PD1 therapeutic efficacy in advanced gastric cancer.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Kudo-Saito+C%22">Kudo-Saito C</searchLink>; Department of Immune Medicine, National Cancer Center Research Institute, Tokyo, Japan. ckudo@ncc.go.jp.<br /><searchLink fieldCode="AU" term="%22Imazeki+H%22">Imazeki H</searchLink>; Department of Immune Medicine, National Cancer Center Research Institute, Tokyo, Japan.; Department of Gastrointestinal Medical Oncology, National Cancer Center Hospital, Tokyo, Japan.<br /><searchLink fieldCode="AU" term="%22Nagashima+K%22">Nagashima K</searchLink>; Biostatistics Unit, Clinical and Translational Research Center, Keio University Hospital, Tokyo, Japan.<br /><searchLink fieldCode="AU" term="%22Shoji+H%22">Shoji H</searchLink>; Department of Gastrointestinal Medical Oncology, National Cancer Center Hospital, Tokyo, Japan.<br /><searchLink fieldCode="AU" term="%22Tsugaru+K%22">Tsugaru K</searchLink>; Division of Gastroenterology and Hepatology, Keio University Hospital, Tokyo, Japan.<br /><searchLink fieldCode="AU" term="%22Takahashi+N%22">Takahashi N</searchLink>; Department of Gastroenterology, Saitama Cancer Center, Saitama, Japan.<br /><searchLink fieldCode="AU" term="%22Kawakami+T%22">Kawakami T</searchLink>; Division of Gastrointestinal Oncology, Shizuoka Cancer Center, Shizuoka, Japan.<br /><searchLink fieldCode="AU" term="%22Amanuma+Y%22">Amanuma Y</searchLink>; Clinical Trial Promotion Department, Chiba Cancer Center, Chiba, Japan.<br /><searchLink fieldCode="AU" term="%22Wakatsuki+T%22">Wakatsuki T</searchLink>; Department of Gastrointestinal Medical Oncology, Cancer Institute Hospital of JFCR, Tokyo, Japan.<br /><searchLink fieldCode="AU" term="%22Nagashima+F%22">Nagashima F</searchLink>; Department of Medical Oncology, Faculty of Medicine, Kyorin University, Tokyo, Japan.<br /><searchLink fieldCode="AU" term="%22Narita+Y%22">Narita Y</searchLink>; Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan.<br /><searchLink fieldCode="AU" term="%22Yamamoto+Y%22">Yamamoto Y</searchLink>; Department of Gastroenterology, University of Tsukuba Hospital, Tsukuba, Japan.<br /><searchLink fieldCode="AU" term="%22Kizawa+R%22">Kizawa R</searchLink>; Department of Medical Oncology, Toranomon Hospital, Tokyo, Japan.<br /><searchLink fieldCode="AU" term="%22Muro+K%22">Muro K</searchLink>; Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan.<br /><searchLink fieldCode="AU" term="%22Boku+N%22">Boku N</searchLink>; Department of Gastrointestinal Medical Oncology, National Cancer Center Hospital, Tokyo, Japan.; Department of Medical Oncology and General Medicine, IMS Hospital, Institute of Medical Science, University of Tokyo, Tokyo, Japan.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%228605732%22">Cancer immunology, immunotherapy : CII</searchLink> [Cancer Immunol Immunother] 2025 Nov 18; Vol. 74 (12), pp. 379. <i>Date of Electronic Publication: </i>2025 Nov 18.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Springer+Verlag%22">Springer Verlag </searchLink><i>Country of Publication: </i>Germany <i>NLM ID: </i>8605732 <i>Publication Model: </i>Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1432-0851 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2203407004%22">03407004 </searchLink><i>NLM ISO Abbreviation: </i>Cancer Immunol Immunother <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=41251805
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1007/s00262-025-04239-1
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 379
    Titles:
      – TitleFull: The FSTL1-DIP2A axis is a significant biomarker for predicting anti-PD1 therapeutic efficacy in advanced gastric cancer.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Kudo-Saito C
      – PersonEntity:
          Name:
            NameFull: Imazeki H
      – PersonEntity:
          Name:
            NameFull: Nagashima K
      – PersonEntity:
          Name:
            NameFull: Shoji H
      – PersonEntity:
          Name:
            NameFull: Tsugaru K
      – PersonEntity:
          Name:
            NameFull: Takahashi N
      – PersonEntity:
          Name:
            NameFull: Kawakami T
      – PersonEntity:
          Name:
            NameFull: Amanuma Y
      – PersonEntity:
          Name:
            NameFull: Wakatsuki T
      – PersonEntity:
          Name:
            NameFull: Nagashima F
      – PersonEntity:
          Name:
            NameFull: Narita Y
      – PersonEntity:
          Name:
            NameFull: Yamamoto Y
      – PersonEntity:
          Name:
            NameFull: Kizawa R
      – PersonEntity:
          Name:
            NameFull: Muro K
      – PersonEntity:
          Name:
            NameFull: Boku N
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 18
              M: 11
              Text: 2025 Nov 18
              Type: published
              Y: 2025
          Identifiers:
            – Type: issn-electronic
              Value: 1432-0851
          Numbering:
            – Type: volume
              Value: 74
            – Type: issue
              Value: 12
          Titles:
            – TitleFull: Cancer immunology, immunotherapy : CII
              Type: main
ResultId 1